Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Provide Corporate Update

May 14, 2020
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, May 21, 2020.  Xenon management will host a conference call and live audio webcast at … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Provide Corporate Update

A Letter to the Hon. Navdeep Bains, Minister of Innovation, Science and Industry

May 14, 2020

May 12, 2020 The Honourable Navdeep Bains, P.C., M.P. Minister of Innovation, Science and Industry C.D. Howe Building 235 Queen Street Ottawa, Ontario K1A 0H5 Dear Minister Bains; On behalf of the member companies of the undersigned associations, we are writing to you regarding the announced Industrial Assistance Program (IAP) support the government is making … Continue reading A Letter to the Hon. Navdeep Bains, Minister of Innovation, Science and Industry

Qu Biologics’ First-in-Class Platform Technology Uniquely Positioned to Address the COVID-19 Pandemic by Arming the Innate Immune System – Our First Line of Defense

May 14, 2020
Qu Biologics Inc.

Qu’s Site-Specific Immunomodulator (SSI) technology is recognized to be uniquely suited to address the problem the world is collectively grappling with – a novel emerging viral infection where there is a lack of adaptive immune memory in the population. In the absence of herd immunity and a vaccine, a highly contagious virus, such as SARS-CoV-2, … Continue reading Qu Biologics’ First-in-Class Platform Technology Uniquely Positioned to Address the COVID-19 Pandemic by Arming the Innate Immune System – Our First Line of Defense

Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 14, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – May 14, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today reported financial results for the third quarter of fiscal year 2020 (“3Q20”) which ended … Continue reading Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates

May 13, 2020
DelMar Pharmaceuticals Inc.

SAN DIEGO, May 13, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the three and nine months ended March 31, 2020 and provided a corporate update. “We continue to be pleased with the rapid enrollment … Continue reading DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates

NRC – IRAP EUREKA Call for Proposal by May 15, 2020

May 12, 2020
NRC - IRAP Canada

Introduction CIIP is pleased to announce its collaboration with NRC-IRAP on the EUREKA call for proposal. This call for proposals for joint research and development (R&D) projects addressing short to medium term solutions for COVID-19 difficulties is now open to Canadian small and medium-sized enterprises (SMEs) who wish to collaborate on R&D projects with partners … Continue reading NRC – IRAP EUREKA Call for Proposal by May 15, 2020

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

May 12, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – May 8, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year 2020 ending March … Continue reading InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

May 12, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – May 12, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that it has filed a Patent Cooperation Treaty (“PCT”) application pertaining to the … Continue reading InMed Files PCT Patent Application for Neuroprotection in Glaucoma

Arbutus to Present at UBS Virtual Global Healthcare Conference

May 12, 2020
Arbutus Biopharma Corp.

WARMINSTER, Pa., May 12, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 11:40 AM ET. A live webcast of the … Continue reading Arbutus to Present at UBS Virtual Global Healthcare Conference

Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections

May 11, 2020
Arbutus Biopharma Corp.

Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET   WARMINSTER, Pa., May 11, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports its first quarter … Continue reading Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections